Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2018-07-30 Interim / Quarterly Rep…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Interim Results for the Six Months Ended 30 June 2018
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Results for the Six Months Ended 30 June 2018' for Arix Bioscience plc. It contains comprehensive financial statements, including the Condensed Consolidated Interim Statement of Comprehensive Income, Statement of Financial Position, and Statement of Changes in Equity. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2018
2018-07-30 English
Arix Bioscience Plc - Notice of Results
Report Publication Announcement Classification · 1% confidence The document is titled 'Arix Bioscience Plc - Notice of Results' and explicitly states that the company 'will announce its interim financial results for the six months ended 30 June 2018 on Monday 30 July 2018.' It also mentions details for an analyst briefing/call related to these results. Since the document is a notification about the future release of financial results (Interim/Half-Year results) rather than the results themselves, it fits the definition of a Report Publication Announcement (RPA). The document length is short (2039 chars), supporting the 'MENU VS MEAL' rule, as it announces the publication of the actual report (which would likely be classified as IR).
2018-07-25 English
Arix Bioscience Plc - Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is very short (1082 characters) and explicitly states the 'Total Voting Rights' as of a specific date (30 June 2018), referencing the DTR 5.6.1 Disclosure Guidance and Transparency Rules. This type of announcement, detailing the total number of shares with voting rights, is a specific regulatory disclosure. It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA). While it relates to shareholder information, it is a direct regulatory notification about the share structure, which fits best under the general 'Regulatory Filings' (RNS) category as a specific disclosure notice, or potentially DVA if it were the *results* of a vote, but here it is just the total rights count. Given the options, RNS is the most appropriate fallback for specific, short regulatory updates that don't fit the other precise categories like DIRS or DIV. It is not a declaration of voting results (DVA), but a statement of the total voting capital.
2018-07-02 English
Arix Bioscience Plc - Autolus annouces closing of IPO
Share Issue/Capital Change Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting that its portfolio company, Autolus Therapeutics, has closed its Initial Public Offering (IPO) in the United States. This announcement details the closing of the offering, the number of shares, the price, and the resulting stake retained by Arix. This type of announcement, which reports on a significant corporate financing/capital event (an IPO of a major holding), fits best under the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns a capital market transaction.
2018-06-26 English
Arix Bioscience Plc - Autolus Announces Pricing of Initial Public Offering
Capital/Financing Update Classification · 1% confidence The document is a press release from Arix Bioscience plc announcing the pricing of an Initial Public Offering (IPO) for one of its portfolio companies, Autolus Therapeutics plc. The content focuses on the financial details of the offering (price, proceeds, Arix's retained stake) and the strategic importance of the event. This type of announcement, detailing fundraising, capital structure changes, or significant investment events like an IPO, aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific financing transaction.
2018-06-22 English
Arix Bioscience Plc - Issue of Shares, Total Voting Rights & PDMR Notification
Remuneration Information Classification · 1% confidence The document explicitly details 'Issue of Ordinary Shares' to non-executive directors and includes multiple sections titled 'PDMR DEALING NOTIFICATION' (Persons Discharging Managerial Responsibilities). This content directly relates to reporting personal share transactions by company directors and executives (insider trades). This matches the definition for Director's Dealing (DIRS). While there is a share issue component, the primary focus and structure revolve around the PDMR notifications.
2018-06-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.